Cargando…

Pharmaceutical treatment of acute bipolar depression

The treatment of bipolar depression is one of the most challenging fields in contemporary psychiatry. The best data concern the antipsychotics quetiapine and the olanzapine-fluoxetine combination. However, the usefulness of antidepressants in bipolar depression remains controversial; positive data a...

Descripción completa

Detalles Bibliográficos
Autor principal: Fountoulakis, Konstantinos N
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports Ltd 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950046/
https://www.ncbi.nlm.nih.gov/pubmed/20948837
http://dx.doi.org/10.3410/M2-47
_version_ 1782187618697478144
author Fountoulakis, Konstantinos N
author_facet Fountoulakis, Konstantinos N
author_sort Fountoulakis, Konstantinos N
collection PubMed
description The treatment of bipolar depression is one of the most challenging fields in contemporary psychiatry. The best data concern the antipsychotics quetiapine and the olanzapine-fluoxetine combination. However, the usefulness of antidepressants in bipolar depression remains controversial; positive data are available for fluoxetine but negative results have been published for paroxetine. Accumulated knowledge so far suggests that bipolar patients need continuous administration of an antimanic agent even during the acute depressive phase. Although our knowledge is indeed limited, the development of guidelines for polypharmacy is necessary and should be done as soon as possible.
format Text
id pubmed-2950046
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medicine Reports Ltd
record_format MEDLINE/PubMed
spelling pubmed-29500462010-10-14 Pharmaceutical treatment of acute bipolar depression Fountoulakis, Konstantinos N F1000 Med Rep Review Article The treatment of bipolar depression is one of the most challenging fields in contemporary psychiatry. The best data concern the antipsychotics quetiapine and the olanzapine-fluoxetine combination. However, the usefulness of antidepressants in bipolar depression remains controversial; positive data are available for fluoxetine but negative results have been published for paroxetine. Accumulated knowledge so far suggests that bipolar patients need continuous administration of an antimanic agent even during the acute depressive phase. Although our knowledge is indeed limited, the development of guidelines for polypharmacy is necessary and should be done as soon as possible. Medicine Reports Ltd 2010-06-23 /pmc/articles/PMC2950046/ /pubmed/20948837 http://dx.doi.org/10.3410/M2-47 Text en © 2010 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Fountoulakis, Konstantinos N
Pharmaceutical treatment of acute bipolar depression
title Pharmaceutical treatment of acute bipolar depression
title_full Pharmaceutical treatment of acute bipolar depression
title_fullStr Pharmaceutical treatment of acute bipolar depression
title_full_unstemmed Pharmaceutical treatment of acute bipolar depression
title_short Pharmaceutical treatment of acute bipolar depression
title_sort pharmaceutical treatment of acute bipolar depression
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950046/
https://www.ncbi.nlm.nih.gov/pubmed/20948837
http://dx.doi.org/10.3410/M2-47
work_keys_str_mv AT fountoulakiskonstantinosn pharmaceuticaltreatmentofacutebipolardepression